Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research.

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

A deal that would have seen Idorsia sell global rights to hypertension drug Tryvio (aprocitentan) has fallen through, leaving the cash-strapped pharma company to seek other avenues to secure funding.

Welcome to the Idorsia Full Year 2024 Financial Results ... in the pharmacological treatment of insomnia by European Sleep Research Society in its recent guidelines. This innovative class has ...

With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate deal with Viatris.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...